Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373094 | 0.93 | TOP2A (0.36) | BCHETOP2A | |
| SCHEMBL6528397 | 0.90 | BCHE (0.31) | BCHE | |
| SCHEMBL14217397 | 0.87 | TK1 (0.33) | — | |
| SCHEMBL2276807 | 0.87 | LMNA (0.34) | — | |
| SCHEMBL2283594 | 0.85 | TK1 (0.39) | — | |
| SCHEMBL2284831 | 0.84 | TOP2A (0.39) | BCHETOP2A | |
| SCHEMBL2284827 | 0.84 | TOP2A (0.39) | BCHETOP2A | |
| SCHEMBL2281293 | 0.82 | POLB (0.41) | — | |
| SCHEMBL12373098 | 0.80 | — | — | |
| SCHEMBL12373120 | 0.77 | TK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20050214843-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050170388-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | BCHE 1123/4885TOP2A 255/4885 |
| US-20050170388-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | BCHE 1560/4885TOP2A 324/4885 |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | BCHE 1664/4885TOP2A 364/4885 |
| US-20050214843-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | BCHE 1560/4885TOP2A 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.